Clinical trials
Chronic HBV Infection clinical trials
Below are recruiting chronic hbv infection clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07179575RecruitingPhase 1/Phase 2
Study of LW231 for people with chronic hepatitis B
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
Hangzhou, ZhejiangAges 18–60 - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+ - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT07254208Enrolling by invitation
Long-term study for those who took PBGENE-HBV
This study follows people who have already received the experimental gene therapy PBGENE-HBV for hepatitis B. It aims to monitor long-term safety and health outcomes.
Boston, MassachusettsAges 19–80 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07200908RecruitingPhase 3
Comparing brelovitug and bulevirtide for hepatitis delta
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
GrazAges 18–99 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT06504485Recruiting
Study of bulevirtide for chronic hepatitis B and D
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
MilanAges 18 years+ - NCT07771140RecruitingPhase 1
Study of an experimental injection for chronic hepatitis b
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
HefeiAges 18–65 - NCT05853718RecruitingPhase 4
Tenofovir treatment for hepatitis B during pregnancy
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hangzhou, ZhejiangAges 20–40 - NCT07275554Recruiting
Gene patterns and risk prediction in hepatitis B liver failure
This study looks at how gene changes (methylation) in people with hepatitis B-related liver failure may predict how well they will do. It aims to create a risk score to guide treatment.
Jinan, ShandongAges 18 years+ - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT07573943RecruitingPhase 4
ASC22 with peginterferon to cure chronic hepatitis B
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT06372990Recruiting
Quick T-cell test for hepatitis B and D
This study is testing a new blood test that quickly checks your T-cells (part of your immune system). It is for people with chronic hepatitis B or both hepatitis B and D.
Milan, MIAges 18 years+ - NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65
Hear when a new Chronic HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hbv infection?
- Yes. Clin2 currently lists 46 recruiting chronic hbv infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hbv infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hbv infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.